MYD88 and metabolic dysfunction-associated steatohepatitis: While ALD and NAFLD exhibit largely conserved pathophysiological implications, several divergent molecular pathways have been identified: In macrophage, MyD88 is recruited to Toll-like receptor 4 (TLR4) upon ligand binding and then activates downstream signaling in NASH, while MyD88 seems not to be involved in TLR4 signaling in ASH [42,53,54].